197 related articles for article (PubMed ID: 14612898)
1. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours.
Checkley D; Tessier JJ; Kendrew J; Waterton JC; Wedge SR
Br J Cancer; 2003 Nov; 89(10):1889-95. PubMed ID: 14612898
[TBL] [Abstract][Full Text] [Related]
2. Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts.
Checkley D; Tessier JJ; Wedge SR; Dukes M; Kendrew J; Curry B; Middleton B; Waterton JC
Magn Reson Imaging; 2003 Jun; 21(5):475-82. PubMed ID: 12878256
[TBL] [Abstract][Full Text] [Related]
3. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.
Nicholson B; Gulding K; Conaway M; Wedge SR; Theodorescu D
Clin Cancer Res; 2004 Dec; 10(24):8728-34. PubMed ID: 15623658
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.
Tuccillo C; Romano M; Troiani T; Martinelli E; Morgillo F; De Vita F; Bianco R; Fontanini G; Bianco RA; Tortora G; Ciardiello F
Clin Cancer Res; 2005 Feb; 11(3):1268-76. PubMed ID: 15709198
[TBL] [Abstract][Full Text] [Related]
5. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
Wedge SR; Ogilvie DJ; Dukes M; Kendrew J; Chester R; Jackson JA; Boffey SJ; Valentine PJ; Curwen JO; Musgrove HL; Graham GA; Hughes GD; Thomas AP; Stokes ES; Curry B; Richmond GH; Wadsworth PF; Bigley AL; Hennequin LF
Cancer Res; 2002 Aug; 62(16):4645-55. PubMed ID: 12183421
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
Ciardiello F; Caputo R; Damiano V; Caputo R; Troiani T; Vitagliano D; Carlomagno F; Veneziani BM; Fontanini G; Bianco AR; Tortora G
Clin Cancer Res; 2003 Apr; 9(4):1546-56. PubMed ID: 12684431
[TBL] [Abstract][Full Text] [Related]
8. ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity.
Ryan AJ; Wedge SR
Br J Cancer; 2005 Jun; 92 Suppl 1(Suppl 1):S6-13. PubMed ID: 15928657
[TBL] [Abstract][Full Text] [Related]
9. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.
Williams KJ; Telfer BA; Brave S; Kendrew J; Whittaker L; Stratford IJ; Wedge SR
Clin Cancer Res; 2004 Dec; 10(24):8587-93. PubMed ID: 15623642
[TBL] [Abstract][Full Text] [Related]
10. Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).
Bradley DP; Tessier JL; Checkley D; Kuribayashi H; Waterton JC; Kendrew J; Wedge SR
NMR Biomed; 2008 Jan; 21(1):42-52. PubMed ID: 17458919
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.
Kummar S; Gutierrez ME; Chen A; Turkbey IB; Allen D; Horneffer YR; Juwara L; Cao L; Yu Y; Kim YS; Trepel J; Chen H; Choyke P; Melillo G; Murgo AJ; Collins J; Doroshow JH
Eur J Cancer; 2011 May; 47(7):997-1005. PubMed ID: 21247755
[TBL] [Abstract][Full Text] [Related]
12. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
McCarty MF; Wey J; Stoeltzing O; Liu W; Fan F; Bucana C; Mansfield PF; Ryan AJ; Ellis LM
Mol Cancer Ther; 2004 Sep; 3(9):1041-8. PubMed ID: 15367698
[TBL] [Abstract][Full Text] [Related]
13. Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.
Baker LCJ; Boult JKR; Thomas M; Koehler A; Nayak T; Tessier J; Ooi CH; Birzele F; Belousov A; Zajac M; Horn C; LeFave C; Robinson SP
Br J Cancer; 2016 Sep; 115(6):691-702. PubMed ID: 27529514
[TBL] [Abstract][Full Text] [Related]
14. ZD6474--clinical experience to date.
Heymach JV
Br J Cancer; 2005 Jun; 92 Suppl 1(Suppl 1):S14-20. PubMed ID: 15928653
[TBL] [Abstract][Full Text] [Related]
15. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
Rudin M; McSheehy PM; Allegrini PR; Rausch M; Baumann D; Becquet M; Brecht K; Brueggen J; Ferretti S; Schaeffer F; Schnell C; Wood J
NMR Biomed; 2005 Aug; 18(5):308-21. PubMed ID: 15918178
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition.
Hammarsten P; Halin S; Wikstöm P; Henriksson R; Rudolfsson SH; Bergh A
Clin Cancer Res; 2006 Dec; 12(24):7431-6. PubMed ID: 17189416
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.
Beaudry P; Force J; Naumov GN; Wang A; Baker CH; Ryan A; Soker S; Johnson BE; Folkman J; Heymach JV
Clin Cancer Res; 2005 May; 11(9):3514-22. PubMed ID: 15867254
[TBL] [Abstract][Full Text] [Related]
18. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.
Matsumori Y; Yano S; Goto H; Nakataki E; Wedge SR; Ryan AJ; Sone S
Oncol Res; 2006; 16(1):15-26. PubMed ID: 16783964
[TBL] [Abstract][Full Text] [Related]
19. Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.
Damiano V; Melisi D; Bianco C; Raben D; Caputo R; Fontanini G; Bianco R; Ryan A; Bianco AR; De Placido S; Ciardiello F; Tortora G
Clin Cancer Res; 2005 Aug; 11(15):5639-44. PubMed ID: 16061883
[TBL] [Abstract][Full Text] [Related]
20. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
Yano S; Muguruma H; Matsumori Y; Goto H; Nakataki E; Edakuni N; Tomimoto H; Kakiuchi S; Yamamoto A; Uehara H; Ryan A; Sone S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8789-98. PubMed ID: 16361567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
